Introduction: Worldwide, diabetic nephropathy (DN) is a major contributor to end-stage renal disease. Early detection remains challenging, necessitating the identification of novel biomarkers. Platelet activation and size, as indicated by Mean Platelet Volume (MPV), have emerged as a potential marker for diabetic microvascular complications. To evaluate the association between MPV and DN in type 2 diabetes mellitus (T2DM) patients and assess its utility as an early diagnostic marker.
Materials and methods: One hundred and twenty-five T2DM patients aged >40 years were included in a cross-sectional study at a tertiary care center. Participants were categorized into nephropathy (n = 73) and non-nephropathy (n = 52) groups based on estimated glomerular filtration rate (eGFR) and urine albumin-to-creatinine ratio (UACR). MPV was measured using automated hematology analyzers. Statistical analyses included correlation studies, receiver operating characteristic (ROC) curve analysis, and logistic regression.
Results: The nephropathy group demonstrated significantly elevated MPV levels compared to the nonnephropathy group (12.30 ± 1.55 vs. 9.61 ± 1.2 fl, P < 0.001). MPV showed strong correlations with diabetes duration (rs = 0.543, P < 0.001), eGFR (rs = -0.581, P < 0.001), and UACR (rs = 0.585, P < 0.001). ROC analysis revealed an optimal MPV cutoff of 11.04 fL for predicting nephropathy with 85.6% accuracy, 89.0% sensitivity, and 80.8% specificity. Each unit increase in MPV was associated with a 3.65-fold increased risk of nephropathy (odds ratio: 3.650, 95% confidence interval: 2.320-5.750, P < 0.001).
Conclusions: MPV represents a simple, cost-effective biomarker for early detection of DN in T2DM patients. Its incorporation into routine clinical assessment could facilitate timely intervention and improve patient outcomes.
扫码关注我们
求助内容:
应助结果提醒方式:
